OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
Thailand Moves to Regulate Gold Trading to Curb Baht Strength and Support Economic Growth 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
UK Housing Market Gains Momentum in Early 2026 as Mortgage Rates Fall 
Canada’s Trade Deficit Jumps in November as Exports Slide and Firms Diversify Away From U.S. 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Philips announced that it has started the repairs and replacements of its first-generation respiratory devices that were recalled in the United States. The healthcare unit of the Dutch multinational conglomerate will be addressing the issues in the recalled DreamStation devices numbering to millions.
Based on the recall notice, it was stated that the recalled machines pose potential health risks so customers were immediately told to stop using the affected model units of Philip’s respiratory machines. As Reuters reported, the U.S. Food and Drug Administration (FDA) announced a recall on some models of DreamStation respiratory and ventilator devices in June.
They were found to have become toxic over time as the foam part might deteriorate. When this happens, the machines may potentially cause cancer. Philips received authorization from the FDA to allow rework in the affected units that could reach four million in total.
Almost half of the affected respiratory machines were sold in the U.S. so the latest recall notification is for this country only at this time. For the rest of the world, Philips has issued a field safety notice for the issue which the FDA classified as Class I recall. In any case, the company said that it will take them about a year to replace or repair the machines.
“We fully recognize that the timeframe for remediation of the affected devices places patients in a difficult situation,” Royal Philips’ chief executive officer, Frans van Houten, said in a press release. “We are mobilized to deliver a solution to them as fast as possible. We have significantly increased our production, service and rework capacity, and further intensified our outreach to our customers and their patients.”
The CEO is also urging patients who are using the affected devices to register their units on the website dedicated for the recalls. This will help them with the process of tracking and obtaining details about the machines.
Aside from the ongoing repairs and replacements, Philips continues to communicate with the FDA to address any other details of the recall as well as mitigation plans in the country. The company has reserved $590 million for the recall operation this year.
